United States News All stories

Driven Brands Holdings (NASDAQ:DRVN) reported a rise in profit and revenue for the first quarter of fiscal 2026, supported by robust performance in its quick-lube business even as the company navigates elevated corporate expenses stemming from its recent financial restatements.

Nurix Therapeutics (NASDAQ:NRIX) released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, demonstrating sustained efficacy and high response rates across multiple lines of therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The Lovesac Company (NASDAQ:LOVE) reported a net loss for its fiscal 2027 first quarter, reflecting the persistent operational difficulties home furnishings retailers face as sticky inflation and elevated mortgage rates suppress discretionary consumer spending.

Takeda Pharmaceutical (NYSE:TAK) reported positive topline results from a head-to-head Phase 3 clinical trial for its experimental plaque psoriasis drug, zasocitinib, positioning the oral pill to challenge established autoimmune blockbusters.

Merck Animal Health, a subsidiary of pharmaceutical giant Merck & Co (NYSE:MRK), signed a definitive agreement to acquire TARGAN, a privately held agtech developer specializing in high-speed automated biodevices for commercial hatcheries.

Parsons (NYSE:PSN) has secured a $22 million contract amendment from the Los Angeles County Metropolitan Transportation Authority to expand infrastructure and transit enhancements along the Interstate 605 corridor.

The board of directors of Target (NYSE:TGT) declared a quarterly cash dividend of $1.16 per common share, representing a 1.8% increase over its previous distribution baseline.

Dana Incorporated (NYSE:DAN) has reached a definitive agreement to combine with Eaton's (NYSE:ETN) Mobility business, a blockbuster industrial carve-out that values the division at $5.1 billion and establishes a premier global vehicle powertrain supplier.

Copley Acquisition (NYSE:COPL) and Ignite Proteomics entered into a definitive business combination agreement that will take the biotech firm public at a pro forma enterprise value of $150 million.

Modiv Industrial (NYSE:MDV) announced the declaration of its scheduled cash distributions for both preferred and common shareholders, maintaining capital returns as the real estate investment trust prepares for its upcoming corporate combination.

The Board of Directors of Philip Morris International (NYSE:PM) declared a regular quarterly cash dividend of $1.47 per common share, matching its previous distribution level.

AEVEX (NYSE:AVEX) announced the delivery of a $12.3 million multi-mission DHC-6-300 Twin Otter aircraft to the Oregon Department of Forestry (ODF), providing specialized airborne data gathering capabilities just as the region enters its peak summer wildfire cycle.

WisdomTree (NYSE:WT) announced that its firm-wide assets under management reached an all-time high in May 2026, fueled by record asset volumes across its U.S., European, and Digital Asset segments, alongside the formal closing of a key international acquisition.

Hooker Furnishings (NASDAQ:HOFT) reported a return to profitability for its fiscal 2027 first quarter, driven by sharp gross margin expansion and resilient performance across its core segments, even as soft consumer demand continues to drag on top-line retail furniture sales.

Cellectis (NASDAQ:CLLS) reported highly encouraging clinical updates for its off-the-shelf, gene-edited cancer therapies, highlighting a perfect overall response rate in a target group of leukemia patients.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced highly anticipated clinical data demonstrating that its CRISPR-based gene-editing therapy, CASGEVY, matches its highly successful adult profile when used in younger children.

Johnson & Johnson (NYSE:JNJ) reported positive data from a late-stage clinical trial for its drug Imaavy, strengthening its bid to secure the first regulatory approval for a rare, life-threatening autoimmune blood disorder.

Medicus Pharma (NASDAQ:MDCX) submitted an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi, seeking authorization to launch a genomics-enabled Phase 2a clinical trial evaluating its candidate Teverelix in women with symptomatic endometriosis.

Rafael Holdings (NYSE:RFL) reported its third-quarter fiscal 2026 financial results alongside a critical clinical milestone, finalizing the active clinical phase of its lead rare disease program and clearing the path for a regulatory submission later this year.

Aurora Cannabis (NASDAQ:ACB) reported record global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, capitalizing on its structural pivot toward high-margin prescription markets in Europe and Australia.

Oracle (NYSE:ORCL) reported record fourth-quarter and full-year 2026 financial results, with broad-based growth across its Cloud Infrastructure and Cloud Applications businesses.

Humacyte (NASDAQ:HUMA) announced positive top-line interim results from its V012 Phase 3 clinical trial evaluating its Acellular Tissue Engineered Vessel (ATEV) as a universally implantable conduit for hemodialysis access in female patients.

A Los Angeles County Superior Court jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $32 million to the family of a California woman who died from pleural mesothelioma, concluding that her fatal cancer was directly caused by decades of exposure to asbestos-contaminated talc in the company's iconic baby powder.

A California state court judge has denied post-trial motions by Meta Platforms (NASDAQ:META) and Google’s (NASDAQ:GOOGL) YouTube seeking a new trial, upholding a landmark jury verdict that found the tech giants liable for intentionally designing addictive features that harm the mental health of youth.